ArticleFrontiers in pharmacology2025
Empagliflozin targeting STAT3/Akt/Nrf2 axis promoting diabetic wound healing in rat model.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cardioprotective Effects of Dapagliflozin against Isoproterenol-induced Myocardial Injury in Rats: Biochemical and Histopathological Evidence.International journal of applied & basic medical researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diabetes mellitus (DM) and its complications pose a major global health challenge, with impaired wound healing leading to severe outcomes. Chronic inflammation, excessive proinflammatory cells, and high reactive oxygen species contribute to diabetic wound complications. Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has antioxidant and anti-inflammatory properties, but its impact on wound healing remains unclear. Objective: To investigate the effects of empagliflozin on wound healing in diabetic rats and explore its underlying molecular mechanisms. Methodology: Fifty male Wistar rats were divided into five groups: untreated diabetic rats (STZ group), STZ + plain hydrogel, STZ + empagliflozin hydrogel (1%), STZ + oral empagliflozin (20 mg/kg), and STZ + MEBO Results: Empagliflozin-treated animals had significant wound healing improvements, confirmed by macroscopic and histological assessments, with oral administration being the most effective. Inflammatory markers, including tumor necrosis factor-alpha (TNF- α) and interleukin-6 (IL-6), were markedly reduced, alongside decreased oxidative stress. Both oral and topical empagliflozin significantly upregulated key proteins involved in healing, including phosphorylated STAT3, Akt, Nrf2, SIRT1, and β-catenin. Conclusion: Empagliflozin accelerates wound healing in diabetic rats through its anti-inflammatory and antioxidant properties. Oral empagliflozin exhibited superior efficacy, suggesting systemic effects that extend beyond glycemic control. These findings offer insights into its molecular mechanisms of empagliflozin as a promising therapeutic agent for diabetic wound management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.